Floatz logo

4-demethyl-4-cholestryloxycarbonylpenclomedine

Primary Brain Tumors

DEKK-TEC, Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Primary Brain Tumors cohort.

Asset / SponsorPhaseRating
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Entrectinib
Hoffmann-La Roche
Phase 2CCC
5-ala
Constantinos Hadjipanayis
Phase 2CCC
Capecitabine
Northwell Health
Phase 1/2CCC
(+)-VINCRISTINE
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC

View all 28 →

Same molecule, other indications

4-demethyl-4-cholestryloxycarbonylpenclomedine is also rated in:

Metastatic Malignant Neoplasm to BrainDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →